{
    "clinical_study": {
        "@rank": "137703", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Active Comparator", 
                "description": "2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Active Comparator", 
                "description": "3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to compare artesunate-mefloquine combination therapy given\n      for 2 and 3 days at the same total dose for the treatment of uncomplicated falciparum\n      malaria."
        }, 
        "brief_title": "Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Plasmodium Falciparum Malaria", 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Falciparum"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a randomized, open-label comparison of two versus three days\n      artesunate-mefloquine treatment in patients with uncomplicated falciparum malaria. Primary\n      endpoints will be 63-day parasitological cure rates in the 2 treatment groups. Secondary\n      endpoints will be parasitological failure rates at each of the weekly follow-up visits to\n      Day 56, occurence of treatment-emergent adverse events on days 0, 1 and 2, mefloquine blood\n      concentrations on days 7, 14 and 28, and in vitro drug sensitivity profiles for parasite\n      isolates as measured by inhibitory concentrations. Genotyping of parasites for known markers\n      of drug resistence will be performed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 5 to 70 years inclusive. If aged < 18 years the subject must have a parent or\n             guardian in attendance.\n\n          2. Asexual stages of P. falciparum parasites in a thick or thin blood film with no other\n             visible plasmodial species.\n\n          3. Willing to give informed consent. Parents or guardians of children and adolescents\n             must agree to give informed consent. Assent is necessary in addition to parental\n             informed consent.\n\n          4. Able to tolerate oral therapy.\n\n          5. Willing to attend follow-up appointments and undergo study procedures.\n\n        Exclusion Criteria:\n\n          1. History of anti-malarial drug use within the past two weeks or mefloquine (MQ) use\n             within 4 weeks.\n\n          2. Bleeding tendency (by history or based on medical records).\n\n          3. Severe/complicated malaria as determined by the investigator (coma or seizures,\n             pulmonary edema, shock, renal failure, jaundice, severe anemia, spontaneous bleeding,\n             hyperparasitemia (>5% RBCs infected), or prostration).\n\n          4. History of allergy to or intolerance of study medications.\n\n          5. Mixed malaria infection by Giemsa stain.\n\n          6. Any other condition that in the opinion of the study investigator warrants parenteral\n             antimalarial treatment.\n\n          7. Pregnant woman or nursing mother"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 26, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659281", 
            "org_study_id": "WRAIR-1327"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "6 mg/kg/day for 2 days (total dose 12 mg/kg)", 
                "intervention_name": "Artesunate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "4 mg/kg/day for 3 days", 
                "intervention_name": "Artesunate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1", 
                "description": "15mg/kg at T=0 and 10 mg/kg 6-24 hours later", 
                "intervention_name": "Mefloquine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "8 mg/kg daily for 3 days", 
                "intervention_name": "Mefloquine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mefloquine", 
                "Artesunate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Artesunate", 
            "Mefloquine", 
            "Plasmodium Falciparum", 
            "Thailand", 
            "Uncomplicated Plasmodium Falciparum malaria"
        ], 
        "lastchanged_date": "August 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Borai, Khaosaming and Muang districts", 
                    "country": "Thailand", 
                    "state": "Trat", 
                    "zip": "23000"
                }, 
                "name": "Vector Borne Diseases Control Units (VBDC, malaria clinics)"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand", 
        "overall_official": [
            {
                "affiliation": "Bureau of Vector-Borne Disease, Department of Disease Control, Ministry of Public Health", 
                "last_name": "Wichai - Satimai, M.D., D.T.M. & H.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dept. of Immunology and Medicine, AFRIMS", 
                "last_name": "Mark M. Fukuda, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "Thailand: Ministry of Public Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Determination of parasitological cure rate of directly observed antimalarial therapy", 
            "safety_issue": "No", 
            "time_frame": "63 days from initiation of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659281"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Armed Forces Research Institute of Medical Sciences, Thailand", 
            "investigator_full_name": "Douglas Walsh", 
            "investigator_title": "Dept Chief", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Parasitological cure rates", 
                "safety_issue": "No", 
                "time_frame": "Weekly to Day 56"
            }, 
            {
                "measure": "Occurence of treatment-emergent adverse events", 
                "safety_issue": "No", 
                "time_frame": "3 days"
            }, 
            {
                "measure": "In vitro drug sensitivity profile for individual parasite isolates", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Mefloquine whole blood concentrations", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Armed Forces Research Institute of Medical Sciences, Thailand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Armed Forces Research Institute of Medical Sciences, Thailand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}